Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224056 | 0.98 | MAPK14 (0.46) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL30036409 | 0.98 | MAPK14 (0.46) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL30224398 | 0.95 | CMA1 (0.46) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL2075283 | 0.95 | CMA1 (0.46) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL15579296 | 0.91 | CMA1 (0.49) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL31079938 | 0.91 | CMA1 (0.49) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL61843 | 0.87 | PGR (0.56) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22471469 | 0.86 | MAPK14 (0.45) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL30898715 | 0.86 | MAPK14 (0.45) | PGRMAPK14CMA1AHRPDE4A | |
| SCHEMBL30898646 | 0.85 | CMA1 (0.44) | PGRMAPK14CMA1AHRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192064-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024064316-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | PGR 2278/4885MAPK14 2210/4885CMA1 4050/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | PGR 2278/4885MAPK14 2210/4885CMA1 4050/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | PGR 1332/4885MAPK14 1700/4885CMA1 809/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | PGR 1380/4885MAPK14 1687/4885CMA1 844/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | PGR 2278/4885MAPK14 2210/4885CMA1 4050/4885 |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | PGR 1406/4885MAPK14 25/4885CMA1 1844/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | PGR 1380/4885MAPK14 1687/4885CMA1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.